FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam – Endpoints News
Business News
- FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam Endpoints News
- Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients Yahoo Finance
- BridgeBio wins FDA approval for heart disease drug STAT
- BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer Bloomberg
- ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data Cardiovascular Business
Source: Business News